ClinicalTrials.gg
CompletedNCT07841366phenytoinUpdated Sep 25, 2026

Compairing Micro Needling With Phenytoin Versus Microneedling Alone on Striae Alba

An interventional study of Phenytoin and Micro needling in Treatment of Striae Alba, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2025, registered Sep 2026).
Updated Sep 25, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the efficacy and safety of Microneedling with Phenytoin versus Microneedling alone for the Treatment of Striae alba.The study is a comparative study which will be carried on 30 patients with Striae alba. Each patient will receive four sessions three weeks apart of the following treatment: -Right side: striae on the right side will be treated by microneedling with depth (2 mm)with topical phenytoin 2% solution. -Left side: striae on the left side will be treated by microneedling alone with depth (2 mm) .

The follow up will be during each session and 1 months after the last session. For treated striae alba, Microneedling will be done under aseptic conditions using isopropyl alcohol 70%.

Read the detailed description

The aim of this study is to evaluate the efficacy and safety of Microneedling with Phenytoin versus Microneedling alone for the Treatment of Striae alba.The study is a comparative study which will be carried on 30 patients with Striae alba. Each patient will receive four sessions three weeks apart of the following treatment: -Right side: striae on the right side will be treated by microneedling with depth (2 mm)with topical phenytoin 2% solution. -Left side: striae on the left side will be treated by microneedling alone with depth (2 mm) .

The follow up will be during each session and 1 months after the last session. For treated striae alba, Microneedling will be done under aseptic conditions using isopropyl alcohol 70%.

All Patients will be evaluated during each session and 1 month after the last session.

All patients in this study will be subjected to the following:

  1. Written informed consent will be obtained from all patients after informing them about the steps of the procedures, the expected effects, the possible complications, other alternative treatments, and the importance of photo documentation.
  2. Full history taking:

    • Personal history: Name, age, sex, residency, marital status, education, socio-economic status, special habits of medical importance, and occupational history.
    • Present history: including onset, course, and duration of the lesions.
    • Past history of any medical, or dermatological diseases and drug history.
  3. clinical Examination:

    *General examination: to detect any associated dermatological or systemic disorders.

  4. Local dermatological examination for detection of site, size, distribution and severity of stria alba .

    • Detect severity of striae by Imam, Nelva, Alviera score (INA score) - Number of striae distensae lines, size of the longest striae distensae line, color and presence or absence of itching. The degrees of severity can be calculated per region are mild (score \<3),moderate( score3-6)and sever (score >6).

The follow-up will include the following assessments: Evaluation by

1. Evaluation by Digital Photography Standardized high-resolution digital photographs taken before and after treatment under consistent lighting conditions. 2- Evaluation by Detect severity of striae by Imam, Nelva, Alviera score (INA score) 3-Evaluation of pain subject discomfort will assessed using a 10-centimeter Visual Analog Scale (VAS) on a scale from 0 cm (no pain) and 10 cm (pain as bad as it can be), 0-0.4 cm: No pain, 0.5-4.5 cm: Mild pain, 4.6-7.5 cm: Moderate pain, 7.6-10 cm: Severe pain

4 -Evaluation of Patient satisfaction (PS score) was recorded using the following scale: 0 (not satisfied), 1 (slightly satisfied), 2 (satisfied), 3 (very satisfied), 4 (extremely satisfied).

5-Patients will be assessed for any adverse effects including pain, edema, erosion, necrosis, and hyperpigmention.

02

Conditions studied

  • Treatment of Striae Alba
03

In context

Lead sponsor

Al-Azhar University is the lead sponsor of 532 studies on the registry; 173 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with stria alba.

    • The patient's age ≥18 years.
    • Both sex male and Femal patients
    • At least 3 stria

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation.

    • Keloid or hypertrophic scar tendency
    • Active skin infection at treatment site
    • Use of isotretinoin within the past 6 months
    • Bleeding disorders or anticoagulant therapy
    • History of to phenytoin
    • Chronic systemic diseases affecting wound healing (e.g., uncontrolled diabetes)
    • Previous striae treatment within the last 6 months
    • Unrealistic expectations or poor compliance
    • Premalignant or malignant lesions in the treatment area
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Micro needling +Topical Phenytoin

    striae on the right side will be treated by microneedling with depth (2 mm)with topical phenytoin 2% solution. A 2% Phenytoin topical solution will be prepared by dissolving the accurate amount of Phenytoin sodium in purified water using a magnetic stirrer. 15% propylene glycol will be added to this solution as a cosolvent and a viscosity modifier. The formulation will be stirred using magnetic stirring up to complete dissolving. Finally, the prepared solution will be dispensed in an amber-colored glass bottle.

    Drug: Phenytoin · Device: Micro needling

  • Active comparator
    Micro needling alone

    striae on the left side will be treated by microneedling alone with depth (2 mm).

    Device: Micro needling

Interventions

  • striae on the right side will be treated by microneedling with depth (2 mm)with topical phenytoin 2% solution. A 2% Phenytoin topical solution will be prepared by dissolving the accurate amount of Phenytoin sodium in purified water using a magnetic stirrer. 15% propylene glycolwill be added to this solution as a cosolvent and a viscosity modifier. The formulation will be stirred using magnetic stirring up to complete dissolving. Finally, the prepared solution will be dispensed in an amber-colored glass bottle.

  • DeviceMicro needling

    striae on the left side will be treated by microneedling alone with depth (2 mm) .

06

What researchers measure

Primary outcomes

  1. Change in INA score of striae alba between treatment sides

    Change in the INA score of striae alba from baseline to after completion of the four treatment sessions for each treatment side. The change in INA score will be compared between the right side treated with micro needling plus topical phenytoin and the left side treated with micro needling alone.,

    Time frame: baseline (before Session 1) and Week 9 (after completion of Session 4)

  2. Change in INA score of striae Alba between treatment sides.

    \- The change in (INA) score of striae alba from baseline and 1 month after the last session for each treatment side. The change in INA score will be compared between the right side treated with microneedling plus topical phenytoin and the left side treated with microneedling alone.

    Time frame: Baseline (before Session 1), and 1 month after the last treatment session(weak 13).

Secondary outcomes

  1. Change in pain score

    Pain intensity will be assessed using a visual analogue scale (VAS)on a scale from 0 cm (no pain) and 10 cm (pain as bad as it can be), 0-0.4 cm: No pain, 0.5-4.5 cm: Mild pain, 4.6-7.5 cm: Moderate pain, 7.6-10 cm: Severe pain during each treatment session for both treatment sides. Pain scores will be compared between the right side treated with microneedling plus topical phenytoin and the left side treated with microneedling alone.

    Time frame: During each treatment session at Baseline (before Session 1), Week 3 (before Session 2), Week 6 (before Session 3), and Week 9 (before Session 4).

  2. Change in Patient Satisfaction (PS) Score

    Patient satisfaction will be assessed using the Patient Satisfaction (PS) score 0 (not satisfied), 1 (slightly satisfied), 2 (satisfied), 3 (very satisfied), 4 (extremely satisfied) after treatment( weak 9), and 1 month after the last treatment session for each treatment side. Changes in PS scores will be compared between the right side treated with micro needling plus topical phenytoin and the left side treated with micro needling alone.

    Time frame: Baseline, after treatment at fourth session(weak 9) , and 1 month after the last treatment session(weak13).

07

Study locations

1 site
  • Al-Azhar University, Faculty of Medicine for Girls
    Cairo, Cairo Governorate 11651, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in May 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 25, 2026
StartActual
Dec 15, 2025
Primary completionActual
May 18, 2026
CompletionActual
Jun 20, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07841366
Responsible party
Doaa Hamza Mahmoud Elbery (Dermatology Resident, Al-Azhar University) — Principal investigator
First posted
Sep 25, 2026
Start date
Dec 15, 2025
Primary completion
May 18, 2026
Completion
Jun 20, 2026
Last update
Sep 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenytoin

Start the discussion